120243-02-9 Usage
Description
Myxochelin A is a microbial metabolite derived from A. disciformis, exhibiting diverse biological activities. It is characterized by its potent inhibition of human 5-lipoxygenase (5-LO) and potential antitumor properties at non-cytotoxic concentrations. Myxochelin A also demonstrates activity against certain Gram-positive bacteria, making it a compound of interest for various applications.
Uses
Used in Pharmaceutical Applications:
Myxochelin A is used as an inhibitor of human 5-lipoxygenase (5-LO) for its potential therapeutic effects on conditions related to 5-LO activity, such as asthma and other inflammatory diseases. Its potent inhibition with an IC50 value of 1.9 μM for the recombinant human enzyme makes it a promising candidate for further research and development in this area.
Used in Anticancer Applications:
Myxochelin A is used as an antitumor agent for its potential to exhibit antitumor activity at non-cytotoxic concentrations. Studies suggest that it may be effective against various types of cancer, and its natural product status could offer advantages in terms of reduced side effects and increased patient compliance.
Used in Antimicrobial Applications:
Myxochelin A is used as an antimicrobial agent, particularly against certain Gram-positive bacteria such as B. cereus, S. aureus, and M. luteus. Its activity in an agar diffusion assay at a concentration of 80 μg/disc indicates its potential for development as a novel antimicrobial compound to combat bacterial infections.
Used in Drug Delivery Systems:
Considering the cytotoxicity of Myxochelin A to 26-L5 colon cancer cells at a concentration of 3 μg/ml, it may be utilized in the development of drug delivery systems specifically designed to target cancer cells while minimizing damage to healthy cells. This could involve the use of nanoparticles or other advanced delivery methods to improve the bioavailability and therapeutic outcomes of Myxochelin A in cancer treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 120243-02-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,0,2,4 and 3 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 120243-02:
(8*1)+(7*2)+(6*0)+(5*2)+(4*4)+(3*3)+(2*0)+(1*2)=59
59 % 10 = 9
So 120243-02-9 is a valid CAS Registry Number.
InChI:InChI=1/C20H24N2O7/c23-11-12(22-20(29)14-7-4-9-16(25)18(14)27)5-1-2-10-21-19(28)13-6-3-8-15(24)17(13)26/h3-4,6-9,12,23-27H,1-2,5,10-11H2,(H,21,28)(H,22,29)
120243-02-9Relevant articles and documents
Myxochelin biosynthesis: Direct evidence for two- and four-electron reduction of a carrier protein-bound thioester
Li, Yanyan,Weissman, Kira J.,Mueller, Rolf
, p. 7554 - 7555 (2008)
Microorganisms produce small molecules known as siderophores to scavenge iron from the environment. Insight into iron acquisition in myxobacteria has been provided recently by the sequencing of the gene cluster for the catecholate myxochelins A and B, from the myxobacterium Stigmatella aurantiaca Sg a15. The gene cluster contains enzymes (MxcCDEF) for assembly of 2,3-dihydroxybenzoic acid (DHBA), an amino transferase, MxcL, and a nonribosomal peptide synthetase (NRPS) subunit, MxcG. In the proposed pathway to the myxochelins, two molecules of DHBA are condensed with the two amino groups of lysine, which is itself tethered to the peptidyl carrier protein domain (PCP) of MxcG. The resulting thioester is then reduced by the NADPH-dependent reductase (Red) domain of MxcG to generate an aldehyde intermediate; subsequent Red-catalyzed reduction yields myxochelin A, while transamination by MxcL produces myxochelin B. Although myxochelin A has been obtained successfully in vitro, it has not been possible to date to reconstitute the transamination reaction to give myxochelin B nor to unequivocally establish the intermediacy of the aldehyde. We report here the successful biosynthesis of myxochelin B in vitro. Furthermore, we demonstrate for the first time the existence of an aldehyde intermediate in the four-electron reduction of a PCP-bound thioester. Finally, we show that the relative levels of myxochelin A and B are likely to be controlled by the direct competition of MxcL and the MxcG Red domain for a free aldehyde intermediate. Copyright
